High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer

BJU International

Volumn 110, Issue 11 C, 2012, Pages

  Willems Jones, Amber ^a,b   Kavanagh, Liam ^a,b,c   Clouston, David ^d   Bolton, Damien ^b   Fox, Stephen ^a,b   Thorne, Heather ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Austin Hospital   (Germany)

^d Focus Pathology ^*  (Australia)

Author keywords

BRCA2; HGPIN; Loss of heterozygosity; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; BRCA2 PROTEIN; DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; DNA SEQUENCE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MALE; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; TISSUE SECTION; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; COMPARATIVE STUDY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MUTATION; NEEDLE BIOPSY; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; BRCA2 PROTEIN; DISEASE PROGRESSION; DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

MLCS; MLOWN;

EID: 84873263449     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11519.x     Document Type: Article

References (48)

1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-8
2. Cancer in Australia 2001. Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). 2004
3. Kote-Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-4
4. Hunter DJ, Riboli E, Haiman CA et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5: 977-85
5. Schumacher FR, Berndt SI, Siddiq A et al. Genome-wide association study identifi es new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-75
6. Futreal PA, Liu Q, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120-2 (Pubitemid 24345332)
7. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-9 (Pubitemid 120031871)
8. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71 (Pubitemid 24345325)
9. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-90 (Pubitemid 24325690)
10. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. 1999
11. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-65 (Pubitemid 35154140)
12. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-42 (Pubitemid 41095079)
13. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-3
14. Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995; 10: 1673-5
15. Esteller M, Fraga MF, Guo M et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. H um Mol Genet 2001; 1 0: 3001-7 (Pubitemid 34083486)
16. Gudmundsson J, Johannesdottir G, Bergthorsson JT et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. C ancer Res 1995; 5 5: 4830-2
17. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. M od Pathol 2005; 1 8: 1305-20 (Pubitemid 41348649)
18. Osorio A, de la Hoya M, Rodriguez-Lopez R et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002; 99: 305-9 (Pubitemid 34309491)
19. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002; 62: 4151-6 (Pubitemid 34791087)
20. Hilton JL, Geisler JP, Rathe JA et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94: 1396-406 (Pubitemid 35154144)
21. Willems AJ, Dawson SJ, Samaratunga H et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplifi cation is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008; 14: 2953-61
22. Thomassen M, Kruse TA, Olsen KE, Borg A, Gerdes AM. Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation. Breast Cancer Res Treat 2004; 87: 273-6 (Pubitemid 39505944)
23. Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 2004; 149: 38-43 (Pubitemid 38177556)
24. Davidsson S, Fiorentino M, Andren O et al. Infl ammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011; 20: 2280-7
25. Hu CK, McCall S, Madden J et al. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 62-7 (Pubitemid 43378872)
26. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67
27. King TA, Sakr RA, Muhsen S et al. Is there a low-grade precursor pathway in breast cancer? Ann Surg Oncol 2011; 19: 1115-21
28. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010; 57: 171-92
29. Epstein JI. Precursor lesions to prostatic adenocarcinoma. V irchows Arch 2009; 454: 1-16
30. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 2007; 4: 321-32 (Pubitemid 46901993)
31. Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006; 8: 826-32 (Pubitemid 44564838)
32. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. H um Pathol 1997; 2 8: 143-8 (Pubitemid 27069177)
33. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004; 17: 360-79 (Pubitemid 41646613)
34. Thorne H, Willems AJ, Niedermayr E et al. Decreased prostate cancer-specifi c survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4: 1002-10
35. Mann GJ, Thorne H, Balleine RL et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006; 8: R12
36. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42 (Pubitemid 41232997)
37. Kench JG, Clouston DR, Delprado W et al. Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology 2011; 43: 410-9
38. Wang WZ, Oeschger FM, Lee S, Molnar Z. High quality RNA from multiple brain regions simultaneously acquired by laser capture microdissection. B MC Mol Biol 2009; 1 0: 69
39. Wu L, Patten N, Yamashiro CT, Chui B. Extraction and amplifi cation of DNA from formalin-fi xed, paraffi n-embedded tissues. Appl Immunohistochem Mol Morphol 2002; 10: 269-74
40. Sanders ME, Simpson JF. Can we know what to do when DCIS is diagnosed? O ncology (Huntingt) 2011; 25: 852-6
41. Syrjanen K. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for effi cacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. Eur J Gynaecol Oncol 2011; 32: 17-33
42. Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can defi ne patients with normal colons, benign polyps, and cancers. Br J Cancer 2011; 105: 239-45
43. Baltaci S, Orhan D, Ozer G, Tolunay O, Gogous O. Bcl-2 proto-oncogene expression in low-and high-grade prostatic intraepithelial neoplasia. BJU Int 2000; 85: 155-9 (Pubitemid 30072468)
44. Emmert-Buck MR, Vocke CD, Pozzatti RO et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959-62
45. Gaisa NT, Graham TA, McDonald SA et al. Clonal architecture of human prostatic epithelium in benign and malignant conditions. J Pathol 2011; 225: 172-80
46. Ribeiro FR, Diep CB, Jeronimo C et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. G enes Chromosomes Cancer 2006; 45: 154-63 (Pubitemid 43191022)
47. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. N ature 2011; 4 76: 163-9
48. Skoulidis F, Cassidy LD, Pisupati V et al. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010; 18: 499-509